Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. (OTCQB:CVSI) generates a steady stream of news as a consumer wellness company specializing in hemp extracts, nutraceuticals, and plant-based foods. Company announcements frequently cover financial results, product launches, regulatory developments, and capital markets activity, offering investors and observers insight into how the business is evolving across its wellness and plant-based platforms.
Regular earnings releases detail quarterly and annual performance, including product sales, gross margin trends, operating income or loss, cash balances, and non-GAAP measures such as Adjusted EBITDA. These updates often highlight the contribution of new products launched since early 2023 and discuss how state and federal regulatory environments for CBD affect B2B and B2C sales.
CV Sciences also issues news on new product introductions and brand extensions. Recent examples include the Ignite men’s performance formula under its wellness portfolio, the +PlusHLTH™ cannabinoid-free supplement line, expanded +PlusCBD™ sleep, calm, reserve, and pet products, and the launch of Lunar Fox, a plant-based company offering vegan alternatives to traditional animal-based proteins. These stories illustrate the company’s focus on innovation and diversification across supplements and plant-based foods.
Another recurring theme in CVSI news is regulatory and policy engagement. The company has publicly commented on federal actions related to CBD research and potential Medicare and Medicaid reimbursement for CBD products, as well as state-level legislation such as Texas Senate Bill 3. In addition, SEC Form 8-K filings and related press releases describe material financing agreements, secured promissory notes, and other capital structure developments.
For readers tracking CVSI, this news feed provides context on the company’s operating performance, product pipeline, regulatory posture, and financing activities. Returning to this page allows users to follow how CV Sciences’ hemp-derived wellness, supplement, and plant-based food strategies are reflected in its ongoing disclosures.
CV Sciences reported financial results for the year ended December 31, 2020, with revenues of $24.4 million, a 55% decline from $53.7 million in 2019. The gross margin stood at 45.1%, while the cash balance remained stable at $4.5 million. The company expanded its retail distribution to over 7,300 stores, up from 5,500 the previous year. Despite these advancements, an operating loss of $22.6 million was reported, marking an increase from $17.2 million in 2019, and a negative adjusted EBITDA of $11.6 million.
CV Sciences, Inc. (OTCQB:CVSI) will release its financial results for the fiscal year and fourth quarter ending December 31, 2020, on March 18, 2021. The company will conduct a conference call on the same day at 1:30 p.m. PT, which can be accessed via the Investor Relations section of its website. The PlusCBD™ brand leads the hemp-derived CBD market in over 7,300 retail locations and is compliant with Good Manufacturing Practices (GMP). The company emphasizes its commitment to scientific research in support of its products.
CV Sciences has announced a major refresh of its PlusCBD™ product line, introducing over 30 new products in the next 45 days. The updated line features contemporary packaging and innovative products such as extra strength gummies and softgels. Each product now includes a QR code linking to lab reports, ensuring quality assurance. According to CEO Joseph Dowling, extensive market research led to this redesign aimed at broadening consumer appeal and reinforcing brand equity. PlusCBD™ remains the top-selling CBD brand, derived from sustainable U.S. and EU hemp.